This study will evaluate the efficacy and safety of PEGASYS plus ribavirin in male patients with hemophilia A and chronic hepatitis C. All patients will receive PEGASYS 180 micrograms s.c. weekly plus ribavirin 1000-1200mg p.o. daily (depending on body weight) for 48 weeks. Following treatment there will be a 24 week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals.

Inclusion Criteria:

• male patients, >=18 years of age;
• hemophilia A;
• chronic hepatitis C;
• compensated liver disease.

Exclusion Criteria:

• therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment <=6 months before start of study drug;
• hepatitis A, hepatitis B or HIV infection;
• chronic liver disease other than chronic hepatitis C.